Treats asthma. ANDA 202843, held by Hetero Labs. Montelukast Sodium.
As of Nov 21, 2026, ANDA 202843 (Montelukast Sodium), held by Hetero Labs, was first approved by FDA on Sep 10, 2014, with 5 approved supplements and 0 published complete response letters.
Montelukast sodium tablets are a leukotriene receptor antagonist indicated for:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 10, 2014 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Montelukast SodiumEQ 10MG BASE ยท tablet;oral | Montelukast Sodium | Rx |
| Sep 21, 2023 | Supplement 14Labeling ยท Standard review | Approved | None posted |
| Jan 29, 2021 | Supplement 7Labeling ยท Standard review | Approved | None posted |
| Jan 29, 2021 | Supplement 5Labeling ยท Standard review | Approved | None posted |
| Jan 29, 2021 | Supplement 4Labeling ยท Standard review | Approved | None posted |
| Jul 30, 2018 | Supplement 2Labeling ยท Standard review | Approved | None posted |
| Sep 10, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters